Despite a new law ordering Germany's national health care system to pay for drugs at reference prices, those keyed to the lowest-priced alternative drugs, Pfizer said it will not reduce the amount it charges for Lipitor, sold in Germany as Sortis. To meet the demand of the new law, set to take effect in January, Pfizer said it would have to cut its price by 38%. As a result, subscribers to the national health plan will have to make up the difference. In South Africa, another argument over drug pricing has led the pharmaceutical industry and health plans to blame each other for the high price of medicines in that country.

Related Summaries